Biallelic RXFP2 variants lead to congenital bilateral cryptorchidism and male infertility, supporting a role of RXFP2 in spermatogenesis.

RXFP2 cryptorchidism male infertility spermatogenesis testicular descent

Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
02 Sep 2024
Historique:
received: 12 03 2024
revised: 02 07 2024
medline: 2 9 2024
pubmed: 2 9 2024
entrez: 2 9 2024
Statut: aheadofprint

Résumé

Does RXFP2 disruption impair male fertility? We identified biallelic variants in RXFP2 in patients with male infertility due to spermatogenic arrest at the spermatid stage, supporting a role of RXFP2 in human spermatogenesis, specifically in germ cell maturation. Since RXFP2, the receptor for INSL3, plays a crucial role in testicular descent during prenatal development, biallelic variants lead to bilateral cryptorchidism, as described in four families to date. While animal models have also suggested a function in spermatogenesis, the postnatal functions of RXFP2 and its ligand INSL3, produced in large amounts by the testes from puberty throughout adulthood, are largely unknown. A family with two male members affected by impaired fertility due to spermatogenic maturation arrest and a history of bilateral cryptorchidism underwent clinical, endocrinological, histological, genomic, in vitro cellular, and in silico investigations. The endocrinological and histological findings were correlated with publicly available single-cell RNA sequencing (scRNA-seq) data. The genomic defects have been characterized using long-read sequencing and validated with in silico modeling and an in vitro cyclic AMP reporter gene assay. An intragenic deletion of exon 1-5 of RXFP2 (NM_130806.5) was detected in trans with a hemizygous missense variant c.229G>A, p.(Glu77Lys). The p.(Glu77Lys) variant caused no clear change in cell surface expression or ability to bind INSL3, but displayed absence of a cAMP signal in response to INSL3, indicating a loss-of-function. Testicular biopsy in the proband showed a maturation arrest at the spermatid stage, corresponding to the highest level of RXFP2 expression in scRNA-seq data, thereby providing a potential explanation for the impaired fertility. Although this is so far the only study of human cases that supports the role of RXFP2 in spermatogenic maturation, this is corroborated by several animal studies that have already demonstrated a postnatal function of INSL3 and RXFP2 in spermatogenesis. This study corroborates RXFP2 as gene implicated in autosomal recessive congenital bilateral cryptorchidism due to biallelic variants, rather than autosomal-dominant cryptorchidism due to monoallelic RXFP2 variants. Our findings also support that RXFP2 is essential in human spermatogenesis, specifically in germ cell maturation, and that biallelic disruption can cause male infertility through spermatogenic arrest at the spermatid stage. Funding was provided by the Bellux Society for Pediatric Endocrinology and Diabetology (BELSPEED) and supported by a Research Foundation Flanders (FWO) senior clinical investigator grant (E.D.B., 1802220N) and a Ghent University Hospital Special Research Fund grant (M.C., FIKO-IV institutional fund). The authors declare no conflict of interest. N/A.

Identifiants

pubmed: 39222519
pii: 7747892
doi: 10.1093/humrep/deae195
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Pediatric Endocrinology and Diabetology
Organisme : Research Foundation Flanders
Organisme : Senior Clinical Investigator
ID : 1802220N
Organisme : Ghent University Hospital Special Research Fund

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Hannes Syryn (H)

Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Julie Van de Velde (J)

Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Department of Pediatric Endocrinology, Ghent University Hospital, Ghent, Belgium.

Griet De Clercq (G)

Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Hannah Verdin (H)

Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Annelies Dheedene (A)

Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Frank Peelman (F)

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Andrew Sinclair (A)

Royal Children's Hospital & Department of Paediatrics, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia.

Katie L Ayers (KL)

Royal Children's Hospital & Department of Paediatrics, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia.

Ross A D Bathgate (RAD)

The Florey Institute and Department of Biochemistry and Pharmacology, University of Melbourne, Melbourne, Australia.

Martine Cools (M)

Department of Pediatric Endocrinology, Ghent University Hospital, Ghent, Belgium.
Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.

Elfride De Baere (E)

Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Classifications MeSH